AstraZeneca Gets CRL for Prefilled Pen Version of Lupus Drug Saphnelo
The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) for AstraZeneca's subcutaneous prefilled‑pen version of Saphnelo, its anifrolumab therapy for systemic lupus erythematosus (SLE). The CRL indicates the agency found deficiencies—primarily around additional safety and manufacturing data—requiring further clarification before approval. AstraZeneca had hoped the pen formulation would broaden Saphnelo’s market by offering a more convenient, patient‑friendly delivery compared with the existing intravenous infusion. The setback postpones the anticipated launch timeline and may affect the drug’s competitive positioning.
Carbon Health Files for Bankruptcy, Seeking to Sell or Restructure
Carbon Health, a fast‑growing urgent and primary‑care startup, announced it has filed for Chapter 11 bankruptcy protection. The filing aims to either restructure the business or find a buyer. The company, which previously raised more than $800 million and operated hundreds...
First 10 Medicare-Negotiated Drug Prices Have Taken Effect: Are Seniors Really Saving Money?
The first ten drugs subject to Medicare price negotiations under the Inflation Reduction Act took effect in early 2024, with the government projecting billions of dollars in annual savings. Early data indicate that the negotiated caps have lowered list prices...
New CagriSema Data Show Improvement over Semaglutide
Novo Nordisk disclosed Phase III data showing its next‑generation metabolic therapy CagriSema outperformed the GLP‑1 blockbuster semaglutide in type 2 diabetes. The trial reported larger reductions in HbA1c and greater body‑weight loss while maintaining a comparable safety profile. CagriSema’s superiority was observed...
GSK Returns Rights to Wave's RNA Editing Program for AATD
GlaxoSmithKline has terminated its collaboration with Wave Life Sciences, returning all rights to the RNA‑editing program aimed at treating alpha‑1 antitrypsin deficiency (AATD). The decision ends a partnership that was closely watched as a potential first‑in‑class RNA‑editing therapy. GSK will...
FDA Rejects Aquestive's Allergy Drug over Packaging Issues
The U.S. Food and Drug Administration issued a complete response letter to Aquestive Therapeutics, rejecting its allergy medication because of packaging deficiencies. The agency identified labeling and child‑resistance failures that do not meet federal standards. As a result, the drug’s...
FDA Opens Submissions for PreCheck Program to Speed up US Factory Builds
The U.S. Food and Drug Administration has opened the first round of submissions for its new PreCheck program, designed to accelerate the construction and approval of drug manufacturing facilities. By allowing manufacturers to submit detailed construction plans early, the initiative...
Sanofi’s Venglustat Succeeds in Phase 3 Gaucher Trial but Fails Separate Study in Fabry Disease
Sanofi’s substrate‑reduction therapy venglustat met its primary endpoint in a Phase 3 trial for type 1 Gaucher disease, showing statistically significant reductions in glucosylceramide levels and improved organ volumes. The study enrolled 400 patients across North America and Europe and demonstrated a...
European Law Changes Mean Drugmakers May Have to Grapple with Generic Competition Sooner
European regulators are preparing a suite of new laws that will tighten the timeline for generic and biosimilar entry, shortening data‑exclusivity periods and expanding patent‑linkage requirements. The measures aim to force originator drugmakers to confront competition earlier, potentially shaving 15‑20%...
FDA Says It Explained Issues Early on for Corcept's Rejected Cushing's Syndrome Drug
The U.S. Food and Drug Administration issued a formal rejection of Corcept Therapeutics' experimental treatment for Cushing's syndrome, stating that it had raised serious scientific concerns early in the review process. FDA officials say they communicated these issues to Corcept...
Bitterroot Reverts to Preclinical Biotech in CD47 as CEO Leaves
Bitterroot Bio, a specialist in CD47 immunotherapy, announced that its program has reverted to the pre‑clinical discovery stage after a brief push toward clinical development. The move coincides with the unexpected resignation of its chief executive officer, raising questions about...
CHMP Opposes Lilly’s Mounjaro in Heart Failure, Backs Novo’s Kayshild
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) voted against extending Eli Lilly’s weight‑loss drug tirzepatide (Mounjaro) to treat heart failure, citing insufficient efficacy data. In the same meeting, the CHMP gave a positive opinion to...
Ultragenyx Resubmits Gene Therapy for Rare Neuro Disease to FDA
Ultragenyx has re‑submitted its FDA approval request for UX111, an adeno‑associated virus (AAV) gene‑therapy targeting a rare neurodegenerative disease. The company previously faced a complete response letter last summer, prompting additional pre‑clinical work and safety analyses. UX111 aims to replace...
Quince's Steroid Therapy for Rare Disease Fails, Shares Tank
Quince Therapeutics announced that its once‑monthly steroid‑based therapy for ataxia‑telangiectasia failed to meet the primary endpoint in a pivotal Phase 3 trial. The rare genetic disorder affects roughly 1 in 100,000 children and currently lacks disease‑modifying treatments. Following the data...
Moderna Licenses Phase 3 Asset to Recordati; ProMIS' Private Placement
Moderna has signed a licensing agreement with Italy’s Recordati to transfer a Phase 3 rare‑disease mRNA therapeutic to the European drugmaker. The deal provides Recordati with worldwide commercialization rights, an upfront cash payment estimated at $150 million, and a series of development...
Amgen Ends Partnership with Kyowa Kirin on Immunology Drug, Despite Phase 3 Wins
Amgen abruptly terminated its collaboration with Japan’s Kyowa Kirin on a late‑stage immunology candidate, returning all rights to the partner despite the drug’s recent Phase 3 success. The move aligns with Amgen’s broader strategic shift toward internal R&D priorities and upcoming biosimilar...
Lilly Unveils $3.5B Factory that Will Make Retatrutide and Other Obesity Drugs
Eli Lilly has allocated $3.5 billion to build a new manufacturing complex in Pennsylvania’s Lehigh Valley that will produce its next‑generation obesity injectable retatrutide and related compounds. The plant is designed for flexible, single‑use bioreactor technology and aims to output over a...
Janux Hires CMO After T Cell Engager Deal with Bristol Myers; A Batch of Appointments at Lexeo
Janux Therapeutics announced the appointment of William Go, M.D., Ph.D., as its new chief medical officer, replacing Zachariah McIver. The hire follows a recently disclosed partnership with Bristol Myers Squibb that provides a $50 million upfront payment for Janux’s T‑cell engager...
Reed Jobs' Cancer Biotech Investment Firm Yosemite Eyes $350M Fund
Yosemite, the cancer‑research investment firm led by Reed Jobs, is seeking to raise a fund of up to $350 million. The capital target positions the firm among the largest early‑stage biotech funds currently forming. Jobs leverages his Silicon Valley connections and...
Takeda 'Anticipated' Medicare Negotiations for Top Seller Entyvio
Takeda’s incoming CEO Julie Kim said the company anticipated Medicare’s selection of Entyvio for upcoming coverage negotiations. Entyvio, Takeda’s top-selling inflammatory‑bowel‑disease biologic, generated roughly $2.5 billion in 2023 revenue. While the firm expects a constructive dialogue, it has not disclosed pricing...
Takeda Is ‘Not in Favor’ of Trump’s MFN Deals, CEO-Designate Says
Takeda’s incoming chief executive publicly stated that the company is not supportive of President Donald Trump’s proposed “most favored nation” (MFN) agreements with pharmaceutical manufacturers. The MFN framework would grant U.S. drugmakers preferential pricing and market‑access terms, a move Takeda...
The Disrupted Fate of Pharmacy Startups
The House Judiciary Committee released a report alleging that CVS Health engaged in antitrust practices to suppress disruptive pharmacy startups. The findings highlight potential collusion with insurers and pharmacy benefit managers to limit market entry. Industry observers note that the...
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Sanofi announced a broad portfolio review that will cut several late‑stage drug programs, aiming to streamline its pipeline and improve cost efficiency. The cull affects multiple candidates across therapeutic areas, though specific names were not disclosed. In parallel, Breakthru Medicine...
Summit Says FDA Will Decide to Approve Its Cancer Drug by November
Summit Therapeutics announced that the U.S. Food and Drug Administration has set a target date of November 2024 to render a decision on its flagship cancer immunotherapy. The drug, positioned as a next‑generation immuno‑oncology agent, has completed its pivotal Phase III...
Agomab Anticipates $182M IPO as It Builds Fibrosis Pipeline
Belgian biotech Agomab Therapeutics announced plans for a Nasdaq IPO targeting roughly $182 million in net proceeds. The company intends to sell about 12.5 million shares, roughly priced near $14.50 each. Proceeds will fund the expansion of its fibrosis pipeline, which includes...
Roche Predicts Its Breast Cancer Pill Could Become Its Biggest-Selling Drug
Roche’s oral breast‑cancer therapy is gaining momentum after two positive late‑stage trial readouts demonstrated strong efficacy and tolerable safety. The company has submitted a U.S. FDA filing and expects a decision later this year. An additional pivotal trial will report...
Following Abivax, Formation Bio Licenses miR-124 Drug From China
Formation Bio announced a licensing agreement to acquire rights to a miR‑124‑based drug candidate from a Chinese partner, mirroring the target of French biotech Abivax’s recently successful ulcerative colitis therapy. The deal positions Formation Bio to enter the rapidly expanding...
Sanofi Says Its €15B Dealmaking Budget, R&D Spend Should Help Ease Looming Dupixent Patent Cliff
Sanofi announced a €14‑15 billion budget for mergers and acquisitions in 2026, alongside a bolstered R&D spend of roughly €7 billion. The pharmaceutical giant aims to counter the looming revenue gap from Dupixent’s patent expiration expected around 2027. Management expects the combined...
Tenpoint Gets FDA Nod for Presbyopia Eye Drop and $235M
Tenpoint Therapeutics received FDA approval for its presbyopia eye drop, YUVEZZI, marking the first pharmacologic therapy for age‑related near‑vision loss. A Phase 3 trial demonstrated a statistically significant two‑line improvement in near visual acuity. The company simultaneously announced a $235 million financing...
ChenMed CEO Warns Against GLP-1s for Seniors
ChenMed chief executive Chris Chen announced that the senior‑focused primary‑care network will stop encouraging the use of GLP‑1 drugs such as Ozempic and Wegovy for weight‑loss purposes. The decision follows internal data linking these medications to higher rates of dehydration,...
Round Three of IRA Negotiations Is Expected to Be ‘Manageable’ for Pharma
Analysts say the third round of Medicare drug‑price negotiations under the Inflation Reduction Act will be largely manageable for large pharmaceutical firms. The round focuses on a limited set of high‑cost specialty medicines, with negotiations slated to begin in 2025....
Oral Rogaine Maker Veradermics Looks to Raise $181M From IPO
Veradermics, a biotech developing an oral formulation of minoxidil—the active ingredient in Rogaine—has filed for an initial public offering seeking roughly $181.8 million in net proceeds. The company is in late‑stage clinical testing, reporting efficacy comparable to the established topical product...
FDA Asks Court to Pause Louisiana's Abortion Pill Fight
The U.S. Justice Department, representing the Trump administration, has petitioned a federal court to suspend a Louisiana lawsuit challenging the FDA’s approval of the abortion medication mifepristone. The request comes as the FDA conducts a comprehensive safety and efficacy review...
Lonza Still Intends to Sell Its Capsules and Health Ingredients Business
Swiss CDMO Lonza reaffirmed its intention to sell its capsules and health ingredients division. The transaction, first announced more than a year ago, has not yet been finalized. Lonza cited ongoing negotiations and market conditions as reasons for the delay....
Teva CEO Says It Has Successfully Transitioned Into a Biopharma Company
Teva Pharmaceutical Industries announced that its latest earnings demonstrate a completed shift from a pure‑play generics manufacturer to a biopharma‑focused enterprise. The CEO highlighted that revenue from specialty and branded products now exceeds traditional generic sales, confirming the strategic pivot....
HHS Seeks to Protect Drugmakers From Anti-Kickback Laws Ahead of TrumpRx Launch
The U.S. Department of Health and Human Services announced a draft rule that would create a safe‑harbor exemption for drug manufacturers participating in the upcoming TrumpRx platform. The proposal seeks to shield companies from the federal anti‑kickback statute when they...
Hengrui Blazes Trail as Chinese Drugmakers Aspire to Go Multinational
Jiangsu Hengrui Pharmaceuticals has surged into the global top‑25 biopharma companies by market value, marking a dramatic shift from its previously low international profile. The Chinese firm leveraged a pipeline of innovative oncology and immunology drugs, securing multiple foreign regulatory...
Halozyme Buys Drug Delivery Biotech Surf Bio; Sanofi Backs Sensorion
Halozyme Therapeutics announced a $300 million upfront acquisition of drug‑delivery biotech Surf Bio, adding its PEGylated enzyme platform to Halozyme’s existing portfolio. The deal is expected to broaden Halozyme’s subcutaneous biologics pipeline and accelerate commercialization of next‑generation delivery technologies. Concurrently, Sanofi...
Biopharma Sentiment Index | Q1 2026
The Biopharma Sentiment Index (BPSI) jumped to 90 in Q1 2026, up from 78 in the prior quarter, marking the strongest sentiment shift in four years. All ten core measures improved, driven chiefly by a surge in dealmaking and better access...
Cellares Raises $257M to Fund Global Expansion as It Eyes 2027 IPO
Cellares, a clinical‑stage cell‑therapy manufacturer, closed a $257 million Series D round to accelerate its global expansion and prepare for a public listing. The funding will support the rollout of new manufacturing sites and scale‑up of its allogeneic cell‑therapy platform. Management has...
Lilly Partners with Recombinase-Based Gene Editing Startup Seamless Therapeutics
Eli Lilly has entered a partnership with Seamless Therapeutics, a startup pioneering recombinase‑based gene editing. The collaboration will combine Lilly’s drug development platform with Seamless’s proprietary recombinase enzymes to create precise, permanent DNA modifications for therapeutic applications. Under the agreement,...
Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data
Boehringer Ingelheim announced that its experimental oral therapy for a rare kidney disorder will advance to a pivotal Phase 3 trial. The decision follows a Phase 2 study that demonstrated modest improvements in glomerular filtration rate but produced puzzling efficacy signals across...
CMS Picks Lilly’s Trulicity, Gilead's Biktarvy for Third Round of Medicare Negotiations
CMS announced the selection of Eli Lilly’s GLP‑1 diabetes drug Trulicity and Gilead’s HIV therapy Biktarvy for the third round of Medicare drug price negotiations under the Inflation Reduction Act. The program, now in its third cycle, expands the list...
Hospitals Could Earn More for Buying US-Made Drugs, CMS Proposes
The Centers for Medicare & Medicaid Services (CMS) has unveiled a proposal to raise hospital reimbursement rates for drugs that are manufactured in the United States. Under the plan, the outpatient prospective payment system would grant higher payments for domestically...
Cardiff Execs Depart as Company Drops Mixed Phase 2 Data
Cardiff Oncology (CRDF) saw its shares tumble more than 30% after it released mixed Phase 2 results for its lead oncology candidate. The trial met several secondary endpoints but failed to achieve its primary efficacy goal, prompting uncertainty about the...
FDA Lifts Hold on One of Two Phase 3 Gene Editing Studies by Intellia
Intellia Therapeutics received FDA clearance to resume one of its two pivotal Phase 3 gene‑editing trials targeting hereditary transthyretin amyloidosis (hATTR). The agency had placed a partial clinical hold earlier this year over safety concerns, but after additional data the hold...
Insilico’s Latest Deal Is a $120M Cardiometabolic Drug Discovery Pact with Qilu Pharma
Insilico Medicine has secured a $120 million drug‑discovery partnership with China’s Qilu Pharma, targeting cardiometabolic diseases. The multi‑year pact follows recent collaborations with Servier and Hygtia Therapeutics, expanding Insilico’s AI platform into new therapeutic areas. Qilu will fund and co‑develop AI‑generated...
AstraZeneca Ends Work on Cardio Drug; Lisata and Qilu Terminate Deal
AstraZeneca has terminated its Phase II cardiovascular drug program, pulling the study from the clinical pipeline. The decision coincides with the simultaneous dissolution of a collaboration between biotech Lisata and Chinese partner Qilu, ending a joint development effort. Both moves...
Virtual Women’s Health Company Wisp Buys TBD Health
Wisp, a leading women’s tele‑health platform, announced the acquisition of sexual‑health startup TBD Health. The deal expands Wisp’s service catalog to include at‑home STI testing and broader sexual‑health counseling. By integrating TBD Health’s FDA‑cleared diagnostics, Wisp aims to offer a...
Boehringer Ingelheim Gets an IBD Bispecific From Shanghai-Based Simcere
Boehringer Ingelheim announced a collaboration with Shanghai‑based Simcere Pharmaceutical to develop a bispecific antibody targeting inflammatory bowel disease (IBD). Boehringer will pay an upfront €42 million, with additional milestone payments tied to development and regulatory progress. The deal gives Boehringer a...